Enterome to present world first clinical data with EO2401, its first-in-class off-the-shelf OncoMimics™ therapeutic cancer vaccine, at ASCO 2022

Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces that it will present for the first time proof-of-concept data from clinical trials with EO2401, its first-in-class off-the-shelf OncoMimics™  cancer immunotherapy at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7, 2022 in Chicago and virtually.